Medical Xpress6 天
FDA approves Omvoh for moderately to severely active Crohn's disease
The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Omvoh targets interleukin ...
healthday6 天
FDA Approves Omvoh for Moderately to Severely Active Crohn Disease
THURSDAY, Jan. 16, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults, ...
Too Old to Operate6 天
FDA Approves Omvoh for Moderately to Severely Active Crohn Disease
THURSDAY, Jan. 16, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn disease in adults, ...
clinicaladvisor.com6 天
Omvoh Approved for Moderately to Severely Active Crohn Disease
Mirikizumab-treated patients achieved statistically significant clinical remission and endoscopic response compared with placebo at week 52. The Food and Drug Administration (FDA) has approved ...
Benzinga.com6 天
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
Omvoh demonstrated 53% clinical remission and 46% endoscopic response in Crohn's patients after one year, outperforming placebo. Over 80% of patients maintained endoscopic response after two years ...
Yahoo Finance6 天
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
On Wednesday, the FDA approved Eli Lilly And Co’s (NYSE:LLY) Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for two ...
AOL6 天
FDA Approves Expanded Use Of Eli Lilly's Ulcerative Colitis Drug For Crohn's Disease
Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn’s disease at the time of approval. The approval is based on results from the ...